Baseline patient characteristics and demography were well-matched between the two ... treatment with a salmeterol/fluticasone propionate (FP) combination or budesonide in patients with mild ...

The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol ... for pneumonia was identical between the two therapies (hazard ratio 1.00).

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation (hazard ratio, 1.07; 95 percent ...

there was no significant difference between the treatment groups for these parameters. This may be because of the fourfold higher microgram corticosteroid dose in the BUDgroup, and also because ...